We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > News > Psychedelics > Content Piece

Psychedelics Company to Provide Free LSD to Researchers

By Leo Bear-McGuinness

Published: Jun 09, 2022   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

The psychedelics company Ceruvia Lifesciences is offering to supply LSD, at no cost, to qualified researchers.

According to the company, this particular batch of LSD on offer is the first to have met the stringent current good manufacturing practices (CGMP) standards required by the US Food and Drug Administration (FDA).

In an announcement on May 31, Ceruvia said that the provision of this LSD will be key to “advancing research into LSD’s safety and efficacy” for the treatment of conditions such as cluster headaches, alcohol use disorder, and anxiety disorder.

The company also intends to supply the first US-based trials of LSD in human subjects to take place for decades. These are scheduled to be conducted at NYU Langone's Center for Psychedelic Medicine and John Hopkins’ Center for Psychedelics and Consciousness Research, although neither trial is currently registered on the National Institute of Health’s database of clinical trials.

“Ceruvia Lifesciences is proud to have produced the world’s first CGMP LSD, which we will offer at no cost to help researchers looking to advance the development of LSD treatments for approved use in patients with unmet medical needs,” Carey Turnbull, founder and CEO of Ceruvia Lifesciences, said in a statement.

Any researchers interested in applying for some of Ceruvia’s LSD can do so by completing a form, which can be found here.


Like what you just read? You can find similar content on the topic tags shown below.

Science & Health Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter